ChemicalBook Product Catalog Otamixaban

1/1

Otamixaban

$ 1.00 /1g

Min. Order1g
Purity99%
Cas No193153-04-7
Supply Ability1ton
Update time2020-01-13

career henan chemical co

6YR

China

Chemical Properties

Product Name	Otamixaban
CAS No	193153-04-7
EC-No	200-258-5
Min. Order	1g
Purity	99%
Supply Ability	1ton
Release date	2020/01/13

▼

▲

Common Name

Otamixaban

CAS Number

193153-04-7

Molecular Weight

446.498

Density

1.3±0.1 g/cm3

Boiling Point

N/A

Molecular Formula

C25H26N4O4

Melting Point

N/A

MSDS

N/A

Flash Point

N/A

▼

▲

Use of Otamixaban

Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.IC50 value:Target: Factor Xa Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

Properties
Spectrum

▼

▲

Name

methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate

Synonym

More Synonyms

▼

▲

Description

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> Factor Xa

Research Areas >> Cardiovascular Disease

References

[1]. Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.

[2]. Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28

[3]. Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14(23):2471-81.

[4]. Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007

[5]. Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14(23), 2471-2481.

▼

▲

Density

1.3±0.1 g/cm3

Molecular Formula

C25H26N4O4

Molecular Weight

446.498

Exact Mass

446.195404

PSA

130.73000

LogP

0.58

Index of Refraction

1.619

▼

▲

1ksn

Otamixaban

Company Profile Introduction

Recommended supplier

Send Inquriy

Otamixaban

Use of Otamixaban

Names

Otamixaban Biological Activity

Chemical & Physical Properties

Synonyms

Company Profile Introduction

You may like

Recommended supplier